Chromium-picolinate therapy in diabetes care: Molecular and subcellular profiling revealed a necessity for individual outcome prediction, personalised treatment algorithms & new guidelines

Infectious Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 188-195

  Yeghiazaryan, Kristina ^a   Peeva, Viktoriya ^a   Shenoy, Aparna ^a   Schild, Hans H ^a   Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Chromium picolinate therapy; Diabetes care; Individualised treatment algorithms; Molecular patterns; Navigating diagnostic systems; New guidelines; Personalised medicine; Risk prediction; Subcellular imaging; Therapy response

Indexed keywords

CHROMIUM PICOLINATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE REGULATION; CHRONIC DISEASE; COMET ASSAY; CONTROLLED STUDY; DETOXIFICATION; DNA DAMAGE; DNA FINGERPRINTING; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG SAFETY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL SCIENCE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 79954459362     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611795589717     Document Type: Article

References (35)

1. Rahim, M.A.; Hussain, A.; Azad Khan, A.K.; Sayeed, M.A.; Keramat Ali, S.M.; Vaaler, S. Rising prevalence of type 2 diabetes in rural Bangladesh: a population based study. Diabetes Res. Clin. Pract., 2007, 77(2), 300-305.
2. Nolan, J.J.; O'Halloran, D.; McKenna, T.J.; Firth, R.; Redmond, S. The cost of treating type 2 diabetes (CODEIRE). Ir. Med. J., 2006, 99(10), 307-310.
3. Wild, S.; Roglic, G.; Green, A; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5), 1047-1053.
4. Azimi-Nezhad, M.; Ghayour-Mobarhan, M.; Parizadeh, M.R.; Safarian, M.; Esmaeili, H.; Parizadeh, S.M.; Khodaee, G.; Hosseini, J.; Abasalti, Z.; Hassankhani, B.; Ferns, G. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med. J., 2008, 49(7), 571-576.
5. Cebioglu, M.; Golubnitschaja, O. New tendencies in the epidemiology of Diabetes Mellitus. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality; Golubnitschaja, O., Ed.; Nova Science Publishers, 2009; pp. 151-156.
6. George, B.; Cebioglu, M.; Yeghiazaryan, K. Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J., 2010, 1(1), 13-18.
7. Connolly, V.; Unwin, N.; Sherriff, P.; Bilous, R.; Kelly, W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J. Epidemiol. Community Health, 2000, 54(3), 173-177.
8. Xu, F.; Yin, X.M.; Zhang, M.; Leslie, E.; Ware, R.; Owen, N. Family average income and diagnosed Type 2 diabetes in urban and rural residents in regional mainland China. Diabet. Med., 2006, 23(11), 1239-1246.
9. Kowluru, V.; Kowluru, R.A. Increased oxidative stress in diabetes regulates activation of a small molecular weight G-protein, H-Ras, in the retina. Mol. Vis., 2007, 13, 602-610.
10. King, G.L. The role of inflammatory cytokines in diabetes and its complications. J. Periodontol., 2008, 79(Suppl. 8), 1527-1534.
11. Potenza, M.A.; Gagliardi, S.; Nacci, C.; Carratu', M.R.; Montagnani, M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr. Med. Chem., 2008, 16(1), 94-112.
12. Skljarevski, V.; Veves, A. Impact of diabetes on vasculature: focus on nervous system. Curr. Diabetes Rev., 2005, 1(3), 245-253.
13. Golubnitschaja, O. Clinical proteomics in application to predictive diagnostics and personalized treatment of diabetic patients. Curr. Proteomics, 2008, 5, 35-44.
14. Golubnitschaja, O. Diabetes mellitus. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality; Golubnitschaja, O., Ed.; Nova Science Publishers, 2009, pp. 147-150.
15. Golubnitschaja, O. Advanced Diabetes care: three levels of prediction, prevention & personalized treatment. Curr. Diabetes Rev., 2010, 6(1), 42-51.
16. Cebioglu, M.; Schild, H.H.; Golubnitschaja, O. Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infect. Disord. Drug Targets, 2008, 8(2), 76-87.
17. Cebioglu, M.; Schild, H.H., Golubnitschaja, O. Diabetes Mellitus as a risk factor for cancer: is predictive diagnosis possible? In: Predictive Diagnostics and Personalized Treatment: Dream or Reality; Golubnitschaja, O., Ed.; Nova Science Publishers, 2009, pp. 247-262.
18. Cebioglu, M.; Schild, H.H.; Golubnitschaja, O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J., 2010, 1(1), 130-137.
19. Antić, M.; Jotić, A.; Radović, M.; Seferović, J. P.; Lalić, N. M.; Jovanović, D.; Lezaić, V. Risk factors for the development of diabetic nephropathy. Srp. Arh. Celok. Lek., 2009, 137, 18-26.
20. Lewis, E. J.; Lewis, J. B. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin. Exp. Nephrol., 2003, 7(1), 1-8.
21. Noh, J. H.; Kim, S. K.; Cho, Y.J.; Nam, H. U.; Kim, I. J.; Jeong, I.K.; Choi, M. G.; Yoo, H. J.; Ahn, Y. H.; Bae, H. Y.; Jang, H. C. Current status of diabetes management in elderly Koreans with diabetes. Diabetes Res. Clin. Pract., 2007, 77(Suppl. 1), S71-S75.
22. Jana, M.; Rajaram, A.; Rajaram, R. Chromium picolinate induced apoptosis of lymphocytes and the signaling mechanisms thereof. Toxicol. Appl. Pharmacol., 2009, 237(3), 331-344.
23. Vincent, J. B. Elucidating a biological role for chromium at a molecular level. Acc. Chem. Res., 2000, 33(7), 503-510.
24. Andersson, M. A.; Petersson Grawé, K. V.; Karlsson, O. M.; Abramsson-Zetterberg, L. A.; Hellman, B. E. Evaluation of the potential genotoxicity of chromium picolinate in mammalian cells in vivo and in vitro. Food Chem. Toxicol., 2007, 45(7), 1097-1106.
25. Rhodes, M.C.; Hébert, C.D.; Herbert, R.A.; Morinello, E.J.; Roycroft, J.H.; Travlos, G.S.; Abdo, K.M. Absence of toxic effects in F344/N rats and B6C3F1 mice following subchronic administration of chromium picolinate monohydrate. Food Chem. Toxicol., 2005, 43, 21-29.
26. Bailey, M. M.; Sturdivant, J.; Jernigan, P. L.; Townsend, M. B.; Bushman, J.; Ankareddi, I.; Rasco, J. F.; Hood, R. D.; Vincent, J. B. Comparison of the potential for developmental toxicity of prenatal exposure to two dietary chromium supplements, chromium picolinate and [Cr3O(O2CCH2CH3)(6(H2O)3]+, in mice. Birth Defects Res B Dev. Reprod. Toxicol., 2008, 83(1), 27-31.
27. Speetjens, J. K.; Collins, R. A.; Vincent, J. B.; Woski, S. A. The nutritional supplement chromium(III) tris(picolinate) cleaves DNA. Chem. Res. Toxicol., 1999, 12(6), 483-487.
28. Kareus, S. A.; Kelley, C.; Walton, H. S.; Sinclair, P. R. Release of Cr(III) from Cr(III) picolinate upon metabolic activation. J. Hazard Mater., 2001, 84(2-3), 163-174.
29. Manygoats, K. R.; Yazzie, M.; Stearns, D. M. Ultrastructural damage in chromium picolinate-treated cells: a TEM study. Transmission electron microscopy. J. Biol. Inorg. Chem., 2002, 7(7-8), 791-798.
30. Stearns, D. M.; Silveira, S. M.; Wolf, K. K.; Luke, A. M. Chromium(III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyltransferase locus in Chinese hamster ovary cells. Mutat. Res., 2002, 513(1-2), 135-142.
31. Hepburn, D. D.; Xiao, J.; Bindom, S.; Vincent, J. B.; O'Donnell, J. Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 3766-3771.
32. Stallings, D.M.; Hepburn, D. D.; Hannah, M.; Vincent, J. B.; O'Donnell, J. Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster. Mutat. Res., 2006, 610(1-2), 101-113.
33. Golubnitschaja, O.; Moenkemann, H.; Kim, K.; Mozaffari, M. S. DNA damage and expression of checkpoint genes p21(WAF1/ CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem. Pharmacol., 2003, 66(3), 511-517.
34. Gahan, P. B. Circulating nucleic acids in plasma and serum: roles in diagnosis and prognosis in diabetes and cancer. Infect. Disord. Drug Targets, 2008, 8(2), 100-108.
35. Golubnitschaja, O.; Costigliola, V. Common origin but individual outcomes: Time for new guidelines in personalized healthcare. Per. Med., 2010, 7(5), 561-568.